Combined blockade of protein kinase A and Bcl-2 by antisense strategy induces apoptosis and inhibits tumor growth and angiogenesis

Clinical Cancer Research

Volumn 7, Issue 8, 2001, Pages 2537-2544

  Tortora, Giampaolo ^a   Caputo, Rosa ^a   Damiano, Vincenzo ^a   Bianco, Roberto ^a   De Placido, Sabino ^a   Bianco, A Raffaele ^a   Ciardiello, Fortunato ^a   Fontanini, Gabriella ^b   Cuccato, Sabina ^b  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b UNIVERSITY OF PISA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CYCLIC AMP DEPENDENT PROTEIN KINASE; KI 67 ANTIGEN; PROTEIN BCL 2;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER SURVIVAL; COLON CANCER; CONTROLLED STUDY; ENZYME INACTIVATION; FEMALE; HUMAN; HUMAN CELL; MALIGNANT TRANSFORMATION; MITOGENESIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

ANIMALS; APOPTOSIS; CELL DIVISION; CYCLIC AMP-DEPENDENT PROTEIN KINASES; DNA, ANTISENSE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; FEMALE; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; OLIGONUCLEOTIDES; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0034886312     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. cAMP-dependent protein kinase: Role in normal and malignant growth
2. Interactions between the epidermal growth factor receptor and type I protein kinase A: Biological significance and therapeutic implications
3. The RIα subunit of protein kinase A (PKA) binds to Grb2 and allows PKA interaction with the activated EGF-receptor
4. Antisense oligonucleotide inhibition of serine/threonine kinases: An innovative approach to cancer treatment
5. A single-injection protein kinase A-directed antisense treatment to inhibit tumor growth
6. Antisense therapeutics
7. Synergistic inhibition of human cancer cell growth by cytotoxic drugs and mixed backbone antisense oligonucleotide targeting protein kinase A
8. A safety and pharmacokinetic study of a mixed-backbone oligonucleotide (GEM 231) targeting the type I protein kinase A by 2-hour infusions in patients with refractory solid tumors
9. Antitumor activity and pharmacokinetics of a mixed-backbone oligonucleotide targeted to the RIα subunit of protein kinase A following oral administration
10. Oral antisense that targets protein kinase A cooperates with Taxol and inhibits tumor growth, angiogenesis, and growth factor production
11. Dysregulation of apoptosis in cancer
12. Apoptosis and cancer drug targeting
13. BCL-2 family members and the mitochondria in apoptosis
14. Molecular effects of paclitaxel: Myths and reality (a critical review)
15. Bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice
16. Progression to androgen independence is delayed by adjuvant treatment with antisense bcl-2 oligodeoxynucleotides after castration in the LNCaP prostate tumor model
17. Chemosensitization and delayed androgen independent recurrence prostate cancer with the use of antisense bcl-2 oligodeoxynucleotides
18. Chemosensitization of malignant melanoma by BCL2 antisense therapy
19. Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma
20. A Phase I/IIA dose-escalating trial of bcl-2 antisense (G3139) treatment by 14-day continuous intravenous infusion (CI) for patients with androgen-independent prostate cancer or other advanced solid tumor malignancies
21. BCL-2 is phosphorylated and inactivated by an ASKI/Jun N-terminal protein kinase pathway normally activated at G(2)/M
22. Mechanisms and consequences of activation of protein kinase B/Akt
23. Involvement of microtubules in the regulation of Bcl2 phosphorylation and apoptosis through cAMP-dependent protein kinase
24. Deletion of the loop region of Bcl-2 completely blocks paclitaxel-induced apoptosis
25. Growth arrest and induction of apoptosis in breast cancer cells by antisense depletion of protein kinase A-RI α subunit: p53-independent mechanism of action
26. Regulation of bcl-2 protein expression in human neuroblastoma SH-Sy5Y cells: Positive and negative effects of protein kinases C and A respectively
27. Large-scale synthesis, purification, and analysis of oligodeoxynucleotide phosphorothioates
28. Downregulation of RIα subunit of the cAMP-dependent protein kinase induces growth inhibition of human mammary epithelial cells transformed by c-Ha-ras and c-erbB2 protooncogenes
29. Antitumor activity of combined blockade of epidermal growth factor receptor and protein kinase A
30. Evaluation of epidermal growth factor-related growth factors and receptors and of neoangiogenesis in completely resected stage I-IIIA non-small cell lung cancer: Amphiregulin and microvessel count are independent prognostic indicators of survival
31. Current pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors
32. Improved detection of apoptotic cell using a modified in situ TUNEL technique
33. Evaluation of survival data and two new rank order statistics arising in its consideration
34. Cooperative inhibitory effect of novel mixed backbone oligonucleotide targeting protein kinase A in combination with docetaxel and anti-EGFR-receptor antibody on human breast cancer cell growth
35. Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225
36. Phosphorylation and inactivation of BAD by mitochondria-anchored protein kinase A
37. Novel function of the regulatory subunit of protein kinase A: Regulation of cytochrome c oxidase activity and cytochrome c release
38. Tumor development under angiogenic signaling: A dynamical theory of tumor growth, treatment response, and postvascular dormancy
39. Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression